Mitoxantrone Articles

Articles

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.

Cixutumumab, a human monoclonal antibody (HuMAb), targets the insulin-like growth factor receptor. Ramucirumab is a recombinant HuMAb that binds to vascular endothelial growth factor receptor-2. A non-comparative randomised phase II study evaluated cixutumumab or ramucirumab plus mitoxantrone and prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC).

Published September 2, 2015
An overview of current and emerging therapeutic management strategies for patients with metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Joelle El-Amm, MD and Jeanny Aragon-Ching, MD

BERKELEY, CA (UroToday.com) - The treatment of metastatic castrate resistant prostate cancer (mCRPC) has changed drastically over the past few years with the emergence of several new therapies.
Published July 12, 2013
Ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments, "Beyond the Abstract," by Robert J. Amato, DO

BERKELEY, CA (UroToday.com) - Prostate cancer is the second most common cancer among men, with almost 240 000 cases expected to be diagnosed in 2013.^[1]
Published June 18, 2013
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Platelet-derived growth factor receptor-α (PDGFRα) is expressed in primary prostate adenocarcinoma and in associated skeletal metastases. Olaratumab is a fully human monoclonal antibody that binds PDGFRα and blocks downstream signalling.
Published January 2, 2019
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.

The aim of this study was to compare the efficacy and safety of docetaxel, cabazitaxel, docetaxel + estramustine, mitoxantrone in the management of castration-resistant prostate cancer (CRPC).
Published June 19, 2018

Mitoxantrone Articles

Articles

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.

An overview of current and emerging therapeutic management strategies for patients with metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Joelle El-Amm, MD and Jeanny Aragon-Ching, MD

Ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments, "Beyond the Abstract," by Robert J. Amato, DO

Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.

Login